Sign In
Buy BPMC
$129.46
+0 (+0%)
At Close: Oct 17, 2025
Blueprint Medicines Corporation (BPMC) Q2 2024 Earnings Call Transcript
08:40pm, Thursday, 01'st Aug 2024
Blueprint Medicines Corporation (NASDAQ:BPMC ) Q2 2024 Earnings Conference Call August 1, 2024 8:00 AM ET Company Participants Jenna Cohen - Vice President-Investor Relations Kate Haviland - Chief Exe
Blueprint Medicines (BPMC) Reports Q2 Loss, Tops Revenue Estimates
09:05am, Thursday, 01'st Aug 2024
Blueprint Medicines (BPMC) came out with a quarterly loss of $0.80 per share versus the Zacks Consensus Estimate of a loss of $1.28. This compares to loss of $2.19 per share a year ago.
Blueprint Medicines Reports Second Quarter 2024 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance
07:00am, Thursday, 01'st Aug 2024
-- Achieved $114.1 million in AYVAKIT net product revenues in the second quarter 2024 -- -- Raising AYVAKIT net product revenue guidance to $435 million to $450 million for 2024 -- -- Initiated Phase
LOS ANGELES, CA / ACCESSWIRE / July 30, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Blueprint Medicin
LOS ANGELES, CA / ACCESSWIRE / July 29, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Blueprint Medicin
LOS ANGELES, CA / ACCESSWIRE / July 26, 202 4/ The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Blueprint Medicin
LOS ANGELES, CA / ACCESSWIRE / July 25, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Blueprint Medicin
Blueprint Medicines (BPMC) Expected to Beat Earnings Estimates: Should You Buy?
11:07am, Thursday, 25'th Jul 2024
Blueprint Medicines (BPMC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
LOS ANGELES, CA / ACCESSWIRE / July 24, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Blueprint Medicin
LOS ANGELES,CA / ACCESSWIRE / July 23, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Blueprint Medicine
LOS ANGELES, CA / ACCESSWIRE / July 22, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Blueprint Medicin
LOS ANGELES, CA / ACCESSWIRE / July 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Blueprint Medicin
The Schall Law Firm Is Currently Investigating Potential Violations Of Securities Laws For Investors Of Blueprint Medicines Corporation
05:00pm, Thursday, 18'th Jul 2024
LOS ANGELES, CA / ACCESSWIRE / July 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Blueprint Medicin
Blueprint Medicines to Report Second Quarter 2024 Financial Results on Thursday, August 1, 2024
08:00am, Thursday, 18'th Jul 2024
CAMBRIDGE, Mass. , July 18, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a live conference call and webcast at 8:00 a.m.
The Schall Law Firm Is Presently Probing Possible Breaches Of Securities Laws For Blueprint Medicines Corporation Investors
02:45pm, Wednesday, 17'th Jul 2024
LOS ANGELES, CA / ACCESSWIRE / July 17, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Blueprint Medicin
